Fig. 2: Odds ratio of pCR for all 491 patients with HER2 positive breast cancer according to BMI category in different subgroups stratified by clinical parameters (adjusted for age, clinical T stage, hormone receptor status, HER2 staining intensity, Ki67, and neoadjuvant targeted therapy, exception for stratification factor). | npj Breast Cancer

Fig. 2: Odds ratio of pCR for all 491 patients with HER2 positive breast cancer according to BMI category in different subgroups stratified by clinical parameters (adjusted for age, clinical T stage, hormone receptor status, HER2 staining intensity, Ki67, and neoadjuvant targeted therapy, exception for stratification factor).

From: Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis

Fig. 2: Odds ratio of pCR for all 491 patients with HER2 positive breast cancer according to BMI category in different subgroups stratified by clinical parameters (adjusted for age, clinical T stage, hormone receptor status, HER2 staining intensity, Ki67, and neoadjuvant targeted therapy, exception for stratification factor).The alternative text for this image may have been generated using AI.

Two-sided P values were calculated using a multivariate logistic regression model. Un/Nor under/normal weight, Ov/Ob overweight/obesity.

Back to article page